<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380509</url>
  </required_header>
  <id_info>
    <org_study_id>MTL-P2-155</org_study_id>
    <nct_id>NCT01380509</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Metronidazole Capsules Under Fasting Conditions</brief_title>
  <official_title>To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules( G.D. Searle, Inc) Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Par Pharmaceutical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algorithme Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Par Pharmaceutical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the single-dose Bioavailability of Kali and G.D.
      Searle, Inc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the relative Bioavailability of Metronidazole 375 mg Capsules with that of Flagyl
      375 mg Capsules in healthy, adult subjects under fasting conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">October 2002</completion_date>
  <primary_completion_date type="Actual">September 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
    <description>To conclude bioequivalence; 90% geometric confidence interval of the ratio of least-squares means of the test to reference product should be within 80.00% - 125.00% for AUC-unf, AUCo-t and Cmax</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>To Determine the Bioequivalence Study Under Fasting</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received kali product under fasting conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received Searle product under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Capsules, single-dose, fasting</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Flagyl Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flagyl</intervention_name>
    <description>Capsules, single-dose, fasting</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Metronidazole Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects meeting all the following criteria may be included in the study

          -  Availability of subjects for the entire study period and willingness to adhere to
             protocol requirements as evidenced by the informed consent form duly signed by the
             subject.

          -  Males or females aged from 18 to 50 years with a body weight index (BMI) within 19-30;
             demographic data (sex, age, ethnic group, body weight, height and smoking habits) will
             be recorded and reported in the final report.

          -  Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, they must be without any clinical significance and must be recorded as
             such in the CRF (laboratory tests are presented in section 7.1.3)

          -  Healthy according to the laboratory results and physical examination

          -  Subjects should be non-or ex-smokers

        Exclusion Criteria:

          -  Significant history of hypersensitivity to metronidazole or any related products as
             well as sever hypersensitivity reactions (like angioedema) to any drugs.

          -  Presence or history of significant gastrointestinal, liver or kidney disease,or any
             other conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects.

          -  Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, endocrine, immunologic or dermatologic disease.

          -  Females who are pregnant, lactating or are likely to become pregnant during the study
             periods.

          -  Females of childbearing potential who refuse to use an acceptable contraceptive
             regimen throughout the study.

          -  Positive pregnancy test before or during the study.

          -  Presence or history of significant thyroid dysfunction (hypo or hyperthyroidism).

          -  Presence or history of significant hypoadrenalism.

          -  Presence or history of significant blood disorders (thrombocytopenia, hemophilia,
             bleeding, etc.).

          -  Presence or history of significant neurological disorders.

          -  Maintenance therapy with any drug, or significant history of drug dependency, alcohol
             abuse (&gt;3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or
             serious psychological disease.

          -  Any clinically significant illness in the previous 28 days before day 1 of this study.

          -  Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all
             barbiturates, corticosteroids, phenylhydantoins, etc.).

          -  Participation in another clinical trial in the previous 28 days before day 1 of this
             study.

          -  Donation of 500mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies,
             etc.) in the previous 5 days before day 1 of this study.

          -  Positive urine screening of drugs of abuse (drug names are presented in section
             7.1.4.).

          -  Positive results to HIV, HBsAg or anti-HCV tests.

          -  History of fainting upon blood sampling.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Sicard, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algotithme Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2011</study_first_submitted>
  <study_first_submitted_qc>June 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 22, 2011</last_update_submitted>
  <last_update_submitted_qc>June 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alfred Elvin/ Director Biopharmaceutics</name_title>
    <organization>Par Pharmaceutical, Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence, single-dose, fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

